News

HeartFlow recently filed a Form S-1 with the SEC to confirm its intent to complete an initial public offering (IPO) and go ...
HeartFlow plans a $100M IPO to fund R&D and new products despite financial risks. Read about its prospects, challenges, and ...
The company reported revenue of $37.2 million in the first quarter, up 39% year over year, but said it has faced challenges ...
Heartflow Inc. continued the steady rhythm of med-tech companies filing to go public, with an S-1 submitted to the U.S. SEC ...
Heartflow's quarterly loss widened over the year-ago period, the healthcare company disclosed in its paperwork for a U.S.
The U.S. IPO market is witnessing a renewed vigor as investors return following months of sluggish activity triggered by ...
EviCore’s updated coverage guidelines support access to AI-enabled Plaque Analysis to help physicians precisely diagnose and manage patients with coronary artery disease ...
MOUNTAIN VIEW, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc., the leader in AI technology for coronary artery disease (CAD), today announced it will present new data and technology for ...
BACKGROUND: Clinical guidelines recommend different revascularization strategies for nonculprit lesions in patients with ST-segment–elevation myocardial infarction (STEMI) versus non-STEMI (NSTEMI).